and membrane permeability of drugs containing carboxylate or phosphate groups. Ester groups are readily hydrolyzed by many types of esterase and readily convert inactive prodrugs into active parental drugs in the body. [ 10 ] In this study, we investigated the use of carbonic ester prodrugs of b-lap to improve drug compatibility with the PEG-b -PLA carrier while reducing their crystallization propensity. Results showed greatly improved drug loading density (15 wt%) and effi ciency (>90%), high apparent drug solubility (>7 mg mL −1 ), storage stability, effi cient esterase-mediated conversion to β-lap, and the ready ability of reconstitution after lyophilization. Figure 1 shows the synthetic scheme of β-lap prodrug derivatives. We fi rst examined the monoester derivative of β-lap (mC 6 was used as an example). At room temperature, in the presence of zinc powder and sodium dithionite, β-lap was reduced to the hydroquinone intermediate, which then reacted with hexanoic acid (activated by HBTU) to produce mC 6 (73% yield). Although mC 6 formed micelles with relatively high drug loading effi ciency (≈70%, data not shown), it is hydrolytically active (aided by the neighboring hydroxyl group) resulting in unstable micelle composition during storage in the phosphate buffered saline (PBS) buffer (50% conversion after 2 d at 4 °C, data not shown). Consequently, we decided to focus on diester derivatives of b-lap for micelle formulation. Diester prodrugs were synthesized at higher temperature (110 °C) from fattic acid anhydrides using zinc powder as the reducing agent. [ 11 ] For anhydrides with shorter chain lengths (i.e., C 2 to C 6 ), over 80% yields were obtained (Figure 1 ). For β-lap-dC 10 and β-lap-dC 16 prodrugs (abbreviated to dC n in subsequent names), yields decreased to 42% and 14%, respectively. All diester prodrugs were hydrolytically stable in PBS.
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After prodrug syntheses, we performed drug loading studies in PEG-b -PLA micelles ( n M = 10 kDa with 5 kDa for the PEG and PLA blocks). We compared micelle properties from two formulation methods, solvent evaporation versus fi lm hydration ( Figure 2 ). In the solvent evaporation method, prodrugs were fi rst dissolved in an organic solvent (e.g., tetrahydrfuran, or THF) and then added dropwise in water under sonication. [ 12 ] THF solvent was allowed to evaporate during magnetic stirring. For the fi lm hydration method, prodrugs and PEGb -PLA copolymers were fi rst dissolved in acetonitrile. A solid fi lm was formed after acetonitrile evaporation, and hot water (60 °C) was added to form micelles. [ 13 ] For b-lap-dC 2 , neither method allowed formation of stable, high drug loading micelles because of its fast crystallization rate in water (similar to β-lap). Drug loading density was ≈2 wt% (theoretical loading density β-Lapachone (β-lap) is a natural product isolated from the Lapacho tree in the rainforest of South America. [ 1 ] It kills a broad spectrum of cancer cells in an NAD(P)H:quinone oxidoreductase-1 (NQO1, a.k.a. DT-diaphorase, E.C.1.6.5.2)-dependent manner. [ 2 ] In cancer cells overexpressing NQO1, β-lap undergoes a futile redox cycle, resulting in massive production of reactive oxygen species. [ 3 ] For every mole of β-lap, >60 moles of NAD(P)H are consumed and >120 moles of H 2 O 2 are generated in ≈2 min. [ 4 ] Cell death occurs specifi cally in cancer cells, while normal cells with endogenous, low levels of the enzyme are spared. [ 5 ] Despite its therapeutic promise, clinical use of β-lap is greatly hampered by its low water solubility (0.038 mg mL −1 ) and poor pharmacokinetics. Previous and current formulations using hydroxylpropyl β-cyclodextrin (HP•β-CD) (ARQ501, ARQ761, respectively) showed a 400-fold increase in solubility. [ 6 ] However, rapid drug clearance from the blood ( t 1/2, β = 24 min), hemolysis due to HP•β-CD carrier and drug-induced methemoglobinemia were also observed. [ 7 ] Recently, our laboratory reported the development of polymeric micelles for the delivery of β-lap.
[ 7b , 8 ] Previous results show that micelles composed of poly(ethylene glycol)-b -poly( D,L -lactic acid) (PEG-b -PLA), a copolymer that is considered safe by the FDA for drug delivery, signifi cantly improved the safety and antitumor effi cacy over ARQ501. However, the major limitation of this micellar formulation was the low drug loading density (2.2 wt%) and effi ciency (<40%), resulting from the fast crystallization of β-lap (yellow needle crystals). [ 8 ] In this study, we investigated a prodrug strategy to improve the formulation properties of β-lap. Prodrugs have been widely used in pharmaceutical industry to improve the physicochemical and biopharmaceutical properties of parent drugs. [ 9 ] Among these, ester groups are most commonly used to improve lipophilicity at 10 wt%). Other diester derivatives were able to form stable micelles with high drug loading. We chose dC 3 and dC 6 for detailed analyses ( Table 1 ). The solvent evaporation method was able to load dC 3 and dC 6 in micelles at 79% and 100% loading effi ciency, respectively. We measured the apparent solubility (maximum solubility where no micelle aggregation/drug precipitation was found) of β-lap (converted from prodrug) at 4.1 and 4.9 mg mL −1 for dC 3 and dC 6 micelles, respectively. At these concentrations, micelle sizes (40-130 nm range) appeared larger than those fabricated using the fi lm hydration method (30-70 nm) and moreover, the dC 3 micelles from solvent evaporation were stable for only 12 h at 4 °C. In comparison, the fi lm hydration method allowed for a more effi cient drug loading (>95% loading effi ciency), larger apparent solubility (>7 mg mL −1 ) and higher stability (>48 h) for both prodrugs. Close comparison between dC 3 and dC 6 micelles showed that dC 3 micelles had smaller average diameters (30-40 nm) and a narrower size distribution compared with dC 6 micelles (40-70 nm) by dynamic light scattering (DLS) analyses (Table  1 ) . This was further corroborated by transmission electron microscopy that illustrated spherical morphology for both micelle formulations ( Figure 2 ). dC 3 micelles were selected for further characterization and formulation studies.
To investigate the conversion effi ciency of dC 3 prodrugs to β-lap, we chose porcine liver esterase (PLE) as a model esterase for proof of concept studies. In the absence of PLE, dC 3 alone was stable in PBS buffer (pH 7.4, 1% methanol was added to solubilize dC 3 ) and no hydrolysis was observed in 7 d. In the presence of 0.2 U mL −1 PLE, conversion of dC 3 to β-lap was rapid, evident by UV-vis spectroscopy illustrated by decreased dC 3 maximum absorbance peak (240 nm) with concomitant β-lap peak (257 nm, Figure 3 a) increases. For dC 3 micelle conversion studies, we used 10 U mL −1 PLE, where this enzyme activity would be comparable to levels found in mouse serum. [ 14 ] Visual inspection showed that in the presence of PLE, the colorless emulsion of dC 3 micelles turned to a distinctive yellow color corresponding to the parental drug (i.e., β-lap) after 1 h (Figure 3 b) . Quantitative analysis (Equations 1-3 , experimental section) showed that conversion of free dC 3 was completed within 10 min, with a half-life of 5 min. Micelle-encapsulated dC 3 had a slower conversion with a half-life of 15 min. After 50 min, ≈95% dC 3 was converted to β-lap (Figure 3 c) . Comparison of dC 3 conversion with β-lap release kinetics from the micelles indicated that the majority of prodrug hydrolysis occurred inside polymeric micelles in the fi rst hour. More than 85% of dC 3 was converted to β-lap in the fi rst 30 min, while only 4% of β-lap was released from micelles. The release profi le of converted β-lap had an initial burst release (40% total dose), followed by a more sustained release (Figure 3 d) , which is consistent with our previously reported β-lap release kinetics from PEG-b -PLA micelles. [ 15 ] This core-based enzyme prodrug conversion also agrees with studies by Wooley et al., who reported the hydrolysis of micelle cores by proteinase K in cross-linked micelles. [ 16 ] To achieve a solid formulation of dC 3 micelles, we investigated a series of lyoprotectants and examined their impact on the lyophilization-reconstitution properties (Table S1 , Supporting Information). These lyoprotectants consist of sugar molecules (e.g., glucose, mannose, trehalose), sugar derivatives (e.g., mannitol, sorbitol), or macromolecules (e.g., dextran, PEG) and are either currently used in clinical formulations or are considered safe by the FDA in drug formulation applications. [ 17 ] After lyophilization, the dC 3 micelle powder was reconstituted by adding a saline solution to an intended concentration of 5 mg mL −1 (converted to b-lap concentration). The reconstituted solution was fi ltered through a 0.45-mm membrane before analysis. We measured the particle size and polydispersity index before and after lyophilization reconstitution, apparent drug solubility after fi ltration, and recovery yield (Table S1 , Supporting Information). Results show that most of the sugar molecules and derivatives were not effective at protecting dC 3 micelle integrity during the lyophilization-reconstitution process as indicated by the low recovery yield (25%-80%), larger particle size, and elevated polydispersity index. Among these, 10 wt% of mannitol and trehalose (relative to dC 3 micelles) allowed for a relatively high recovery yield (80%-85%) and apparent solubility (4.0-4.2 mg mL −1 β-lap). For the macromolecular lyoprotectants, dextran did not yield satisfactory protection as indicated by low recovery yield (20%-40%). Among all the lyoprotectants, 10 wt% PEG2k or PEG5k allowed for the most optimal outcome with quantitative recovery yield and small changes in particle size and polydispersity (Table S1 , Supporting Information).
To examine whether dC 3 -converted drug maintains NQO1 specifi city, we performed cytotoxicity studies of dC 3 micelles using A549 and H596 human lung cancer cell lines. [ 18 ] A549 cells endogenously express high level of NQO1 and we used dicoumarol, a competitive inhibitor of NQO1, to compete with dC 3 micelles to examine the NQO1 specifi city. [ 19 ] On the other hand, native H596 cells do not express NQO1 due to homozygous *2 polymorphism, and these cells were stably transfected with a CMV-NQO1 plasmid to create a genetically matched cell line expressing NQO1. [ 2 ] Figure 4a doses. After 2 h incubation without PLE addition, almost no cytotoxicity was observed at 10 × 10 −6 M dC 3 micelles in NQO1+ and NQO1− H596 cells (Figure 4 b) . Addition of 10 U mL −1 PLE to the cell culture medium, led to a signifi cant increase in cytotoxicity in NQO1+ H596 (8% survival) versus NQO1− H596 cells (95% survival). Similarly, dC 3 micelle toxicity in A549 cells was abrogated by addition of 50 × 10 −3 M dicoumarol to inhibit NQO1 (Figure 4 a) . Cytotoxic responses for dC 3 micelles in A549 and NQO1+ H596 cells were slightly less than noted for β-lap alone (in dimethyl sulfoxide (DMSO), Figure S1a ,b, Supporting Information), which might attribute to a delay in drug release from micelles. ), which indicates that prodrugs were converted to β-lap in the fi rst hour before release from micelles. dC 3 micelle concentration was at 10 µg mL −1 . In b-d), dC 3 micelles with 9.7 wt% loading density were used. addition of PLE, the LD 50 values of dC 3 micelles to NQO1-defi cient H596 and dicoumarol-protected A549 cells were >10 × 10 −6 M , the highest doses tested. Conversely, a dramatic increase in cytotoxicity was observed in NQO1-expressed cells after adding 10 U mL −1 of PLE to the cell culture medium. The LD 50 values of dC 3 micelles in A549 or NQO1+ H596 cells decreased to 4.5 or 3.1 × 10 −6 M , respectively, highlighting the NQO1-dependent cytotoxicity of dC 3 micelles.
In conclusion, we report a prodrug strategy through the synthesis of diester derivatives of β-lap to increase compatibility with the PEG-b -PLA copolymer using for micelle inclusion, while reducing drug crystallization for improved formulation of NQO1-targeted nanotherapeutics. In this study, our data showed that diester prodrugs of β-lap (except for the diacetyl derivative) have greatly improved drug loading density and efficiency in PEG-b -PLA micelles, which leads to high apparent drug solubility (>7 mg mL −1 ), physical stability, and ability for reconstitution after lyophilization. In the presence of esterase, β-lap prodrugs (i.e., dC 3 ) were effi ciently converted into β-lap within the micelles. Cell culture experiments in vitro demonstrated NQO1-specifi c toxicity in nonsmall cell lung cancer (NSCLC) cells, similar to results previously published by our laboratories in NQO1-overexpressing solid cancers. [ 2 , 4 , 19b ] These results establish β-lap prodrug micelle formulation for further evaluation of safety and antitumor effi cacy in vivo in NQO1-targeted therapy of NSCLC.
Experimental Section
Typical Procedure for the Syntheses of dC n (dC 3 as an Example) : β-Lap (242 mg, 1 mmol), zinc powder (320 mg, 4.9 mmol), 40 mg sodium acetate (0.49 mmol), and 1 mL anhydrous propionic anhydride were mixed and stirred at 110 °C for 1 h. After reaction, the mixture was cooled to room temperature, fi ltered, and washed with 10 mL ethyl acetate. The fi ltrate was distilled under reduced pressure to remove propionic anhydride and ethyl acetate. The residue was dissolved in 20 mL CH 2 Cl 2 and washed with water. The organic extract was dried over sodium sulfate and concentrated. The residue was recrystallized from isopropanol. Yield: 92%. 1 H NMR (400 MHz, CDCl 3 , δ): 8.24 (d, J = 8.0 Hz, 1H; Ar H), 7.69 (d, J = 8.0 Hz, 1H; Ar H), 7.49 (m, 2H; Ar H), 2.70 (t, J = 7.0 Hz, 2H; CH 2 ), 2.62 (t, J = 6.5 Hz, 4H; CH 2 ), 1.87 (t, J = 6.8 Hz, 2H; CH 2 ), 1.43 (s, 6H; CH 3 ), 1.33 (t, J = 7.0 Hz, 6H; CH 3 ); 13 
β-Lap Prodrug Micelle Fabrication by the Film Hydration Method :
Both dC 3 and dC 6 micelles were prepared by the fi lm hydration method following the same protocol. Here, we use dC 3 with 10 wt% theoretical loading density as an example. dC 3 (10 mg) and PEG-b -PLA (90 mg) were dissolved in 5 mL acetonitrile and solvent was removed using a rotary evaporator to form a solid thin fi lm. Normal saline (1 mL) was added to the fi lm at 60 °C and vortexed for 5 min. The resulting micelle solution was stored at 4 °C for 1 h and fi ltered through 0.45 µm membrane fi lters to remove non-encapsulated drug aggregates in solution. The resulting micelles were further analyzed by DLS (Malvern MicroV model DLS, He-Ne laser, λ = 632 nm, for hydrodynamic diameter, all the diameters were read as number average diameters) and transmission electron microscopy (TEM, JEOL 1200 EX model).
Esterase-Mediated Hydrolysis of Free dC 3 and dC 3 Micelles : In a typical procedure, free dC 3 (dissolved in methanol then dispersed in buffer) or dC 3 micelle solution was dispersed in 1 mL PBS buffer (pH 7.4) at a concentration of 10 µg mL −1 in a quartz cuvette. PLE was added to the solution and cuvettes were capped. Solution were kept at 37 °C with shaking. The absorbance spectrum of the solution was measured using a Hitachi UV-vis Spectrophotometer (Fremont, CA) at different times. β-Lap concentrations were determined by Equations ( 1,2) and prodrug conversion was then determined utilizing Equation 3 :
where A 1 and A 2 are absorbances at 240 nm and 257 nm, respectively; ε 1 and ε 2 are extinction coeffi cients of dC 3 and β-lap at 240 nm ( ε 1 = 2.0 × 10 4 M −1 cm −1 , ε 2 = 9.0 × 10 3 M −1 cm −1 ), respectively; ε 3 and ε 4 are extinction coeffi cients of dC 3 and β-lap at 257 nm (
), respectively; L is the path length (1 cm), c 1 and c 2 are the concentration of dC 3 and β-lap. c 0 is the initial concentration of dC 3. Lyoprotectant Screen for the Lyophilization-Reconstitution of dC 3 Micelles : dC 3 micelle formulations (9.7 wt%) were prepared using the fi lm hydration method. The micelle solutions were then mixed with different amounts of lyoprotectant to reach a fi nal lyoprotectant concentration of 5 or 10% w/v. The resulting solutions were transferred into glass vials and adjusted to 0.5 mL for all samples. Lyophilization was performed on a Labconco freeze-dryer (Kansas City, MO). The samples were frozen at −80 °C for 1 h, and primary drying was achieved at −80 °C and 0.006 mbar for 24 h. After lyophilization was fi nished, samples were reconstituted with 0.5 mL saline and analyzed by DLS measurements. After size measurement, reconstituted solutions were fi ltered through 0.45 µm membranes, and fi ltrates were analyzed by UV-vis to determine drug content and recovery.
Cytotoxicity Analyses In Vitro of β-Lap Prodrug Micelles : Cell survival assays based on DNA content were performed in A549 and H596 NSCLC cells as described. [ 18 ] Original H596 cells contain a homozygous *2 NQO1 polymorphism and thereby lack NQO1 expression. Genetically matched NQO1+ counterparts were generated and characterized for responses to β-lap alone as described. [ 20 ] A549 cells endogenously over-express NQO1, and its enzyme activity can be blocked by coadministration of dicoumarol, simulating an NQO1-defi cient cell. Briefl y, NQO1+ or NQO1− H596 or A549 NSCLC cells were seeded (10 000 cells/well) into each well of 48-well plates. A549 cells were seeded similarly. On the following day, media were removed, and replaced with that containing predetermined doses of free β-lap drug (dissolved in DMSO) or dC 3 micelles with or without PLE for 2 h. For A549 cells, dicoumarol at a concentration of 50 × 10 −6 M was coadministered to inhibit NQO1. After 2 h exposures, media were replaced with control growth media and cells were allowed to grow for an additional 7 d. DNA content was determined by Hoescht dye 33258, using an adaptation of the method of Labarca and Paigen. [ 21 ] Samples were read in a PerkinElmer HTS 7000 Bio Assay Reader (Waltham, MA), and data were expressed as means±SE relative growth and graphed as treated/control (T/C) values from six wells per treatment.
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